菜单
Service Overviews

After over 7 years of persistent endeavor, Sanyou Bio has established a state-of-the art and integrated R&D platform for the innovative antibody generation.


The platform is featured by a super-trillion phage display antibody library. Integrated with antibody engineering, in-vitro and in-vivo efficacy evaluation, production cell line construction, lab-scale production and other related- and supported-platforms. Covering the whole process of antibody drug R&D from target research to IND application.

Service Overview After over 7 years of persistent endeavor, Sanyou Bio has established a state-of-the art and integrated R&D platform for the innovative antibody drugs discovery. The platform is featured by a super-trillion phage display antibody library. Integrated with antibody engineering,in-vitroandin-vivoefficacy evaluation, production cell line construction, lab-scale production and other related- and supported-platforms. Covering the whole process of antibody drug R&D from target research to IND application. Service Highlights 1. Complete integration capability Sanyou integrated R&D platform for innovative antibody drug discovery is equipped with 10 functional modules and more than 40 technology platforms, covering the whole pre-clinical R&D process of antibody drug including pre-clinical candidate (PCC) confirmation, pre-clinical CMC development and IND application. 1.1. Confirmation of pre-clinical candidate (PCC) molecules FM1 Raw material preparation Ultra-fast recombinant protein customization High-quality gram-amount antibody customization Overexpression cell line for research purpose FM2 Antibody generation Super-trillion library size of innovative antibody drug discovery platform FM3 In vitro efficacy screening In vitro innovative drug efficacy evaluation FM4 Antibody engineering Deep antibody humanization Ultimate antibody affinity maturation FM5 Efficacy evaluation in animal models Innovative drug efficacy screening in animal models Pharmacokinetic analysis for antibody drugs FM6 Quality analysis Multi-dimensional antibody characterization analysis 1.2. Pre-clinical CMC Development FM7 Cell line development Cell line development for industrial production FM8 Lab-scale process development Antibody drug fermentation process R&D 发 Antibody drug purification process R&D Antibody drug formulation process R&D FM9 Quality control Quality control FM10 Pilot-scale production Pilot-scale production 2. Powerful support from abundant platforms After 7 years of continuous innovation, the series platforms of Sanyou Bio including antibody generation, antibody engineering, in-vitro and in-vivo efficacy evaluation, production cell line construction, and pilot fermentation have formed its unique technical barriers and core competitiveness, which greatly support integrated R&D platform for innovative antibody drugs. 2.1. Featured Platform I:Super-trillion library size of innovative antibody drug discovery platform ✔ Ten-trillion-level library capacity ✔ Thousands of lead molecules for initial screening ✔ Full coverage of molecule forms ✔ Multiple pathways for molecule generation ✔ Fit to challenging targets ✔ In-depth validation through nearly one hundred projects ✔ Matching with one-stop and high-throughput screening service Trillion fully human recombinant antibody library ✔ Trillion library capacity ✔ Recombinant antibody library based on human B cell antibody gene ✔ Derived from nature with high druggability ✔ Median lead molecules: Over 300 Trillion fully human semi-synthetic antibody library ✔ Trillion library capacity ✔ Antibody library based on human B cell antibody gene rearrangement ✔ Derived from nature along with engineering design and high diversity ✔ Median lead molecules: Over 300 2C-type trillion single domain antibody library ✔ 2-trillion library capacity ✔ The humanization degree based on framework is as high as 98% ✔ 2C-type single domain synthetic antibody library ✔ Median lead molecules: Over 600 4C-type trillion single domain antibody library ✔ 2-trillion library capacity ✔ The humanization degree based on framework is as high as 98% ✔ 4C-type single domain synthetic antibody library that is theoretically more stable and more degradation-resistant ✔ Median lead molecules: Over 600 Trillion fully human common light chain monoclonal antibody library库 ✔ Trillion library capacity ✔ Recombinant antibody library with a combination of selected light chains and diversified heavy chains ✔ Derived from fully human naive antibodies, with selected light chains and diversified heavy chains ✔ Median lead molecules: Over 300 Trillion cyclic polypeptide library ✔ Trillion library capacity ✔ A cyclic polypeptide library with fusion of selected tagged proteins and natural cyclic polypeptides ✔ Fit for the R&D of PDC, oral, and intracellular targets ✔ Median lead molecules (estimated): Over 100 Magnetic & Immunization & Tandem mouse antibody library ✔ Large library capacity and definite sequences costing months less compared with hybridoma method ✔ Diversified antigens, mouse, immunization method, and screening method ✔ Recombinant antibody library base on mouse B cell antibody genes after immunization ✔ Median lead molecules: Over 40 Magnetic & Immunization & Tandem alpaca antibody library ✔ Large library capacity and definite sequences ✔ Diversified antigens, mouse, immunization method, and screening method ✔ Single domain antibody obtained directly ✔ Median lead molecules: Over 30 2.2. Featured Platform II: Antibody engineering platform Deep humanization at the level of over 95% ✔ 3D deep humanization design ✔ Distinctive database with reliable design ✔ Rich project experience and high success rate Eukaryotic expression system with natural modification ✔ Fast and qualified delivery within 4 to 6 weeks Ultimate affinity maturation with up to a hundred times of improvement, ✔ Ultimate improvement of affinity activity ✔ Comprehensive verification of eukaryotic expression ✔ No limit on target types ✔ Rich project R&D experience ✔ Fast and qualified delivery within 6 weeks 2.3. Featured Platform III: Platform for efficacy evaluation in animal models ✔ Variety of mouse strains and disease models ✔ Standardized animal room and management system ✔ High-quality and customized one-stop service ✔ Rich project R&D experience ✔ Fast and qualified delivery within 56 days 2.4. Featured Platform IV: Platform for production cell line development ✔ High yield: Expression level of bispecific monoclonal antibody cell line in flask is up to 9.0 g/L ✔ Stable production: Over 60 PDL assessments are performed to support commercialized production. ✔ Premium quality: 11 assessment indicators are used to ensure expression production quality. ✔ Good compliance: cGMP standards are adopted and 4 sets of commercially authorized host cells are available. ✔ Ultra fast: It takes only 2.5 months to obtain monoclonal cell lines. 2.5. Featured Platform V: Platform for antibody fermentation process development ✔ Antibody yield up to 12 g/L ✔ Compliance with antibody quality standards ✔ Four sets of authorized host cells 3. Extensive project experience As of May 2022, Sanyou Bio has developed more than 100 pre-PCC, PCC and pre-clinical projects, and has accumulated rich project experience in antibody drug development targeting different disease fields, molecular types and MOA types, which guarantees the smooth progress of customer projects. Statistics of projects in different disease fields Statistics of projects in different molecular types Statistics of projects in different MOA types

Service Highlights

1. Complete integration capability

Sanyou integrated R&D platform for innovative antibody drug discovery is equipped with 10 functional modules and more than 40 technology platforms, covering the whole pre-clinical R&D process of antibody drug including pre-clinical candidate (PCC) confirmation, pre-clinical CMC development and IND application.


1.1. Confirmation of pre-clinical candidate (PCC) molecules

FM1 Raw material preparation

Ultra-fast recombinant protein customization

High-quality gram-amount antibody customization

Overexpression cell line for research purpose


FM2 Antibody generation

Super-trillion library size of innovative antibody drug discovery platform


FM3 In vitro efficacy screening

In vitro innovative drug efficacy evaluation


FM4 Antibody engineering

Deep antibody humanization

Ultimate antibody affinity maturation


FM5 Efficacy evaluation in animal models

Innovative drug efficacy screening in animal models

Pharmacokinetic analysis for antibody drugs


FM6 Quality analysis

Multi-dimensional antibody characterization analysis


1.2. Pre-clinical CMC Development

FM7 Cell line development

Cell line development for industrial production


FM8 Lab-scale process development

Antibody drug fermentation process R&D

Antibody drug purification process R&D

Antibody drug formulation process R&D


FM9 Quality control

Quality control


FM10 Pilot-scale production

Pilot-scale production

2. Powerful support from abundant platforms

After 7 years of continuous innovation, the series platforms of Sanyou Bio including antibody generation, antibody engineering, in-vitro and in-vivo efficacy evaluation, production cell line construction, and pilot fermentation have formed its unique technical barriers and core competitiveness, which greatly support integrated R&D platform for innovative antibody drugs.


2.1. Featured Platform I:Super-trillion library size of innovative antibody drug discovery platform

✔ Ten-trillion-level library capacity
✔ Thousands of lead molecules for initial screening
✔ Full coverage of molecule forms
✔ Multiple pathways for molecule generation
✔ Fit to challenging targets
✔ In-depth validation through nearly one hundred projects
✔ Matching with one-stop and high-throughput screening service

Trillion fully human antibody library

✔ Trillion library capacity

✔ Recombinant antibody library based on human B cell antibody gene

✔ Derived from nature with high druggability

✔ Median lead molecules: Over 300


Trillion fully human semi-synthetic antibody library
✔ Trillion library capacity
✔ Antibody library based on human B cell antibody gene rearrangement
✔ Derived from nature along with engineering design and high diversity

✔ Median lead molecules: Over 300


Trillion humanized 2C-type single domain antibody library
✔ 2-trillion library capacity
✔ The humanization degree based on framework is as high as 98%
✔ 2C-type single domain synthetic antibody library
✔ Median lead molecules: Over 600

✔ 2-trillion library capacity
✔ The humanization degree based on framework is as high as 98%
✔ 4C-type single domain synthetic antibody library that is theoretically more stable and more degradation-resistant

✔ Median lead molecules: Over 600


✔ Trillion library capacity
✔ Recombinant antibody library with a combination of selected light chains and diversified heavy chains
✔ Derived from fully human naive antibodies, with selected light chains and diversified heavy chains
✔ Median lead molecules: Over 300

Trillion cyclic polypeptide library
✔ Trillion library capacity
✔ A cyclic polypeptide library with fusion of selected tagged proteins and natural cyclic polypeptides
✔ Fit for the R&D of PDC, oral, and intracellular targets
✔ Median lead molecules (estimated): Over 100

✔ Large library capacity and definite sequences costing months less compared with hybridoma method
✔ Diversified antigens, mouse, immunization method, and screening method
✔ Recombinant antibody library base on mouse B cell antibody genes after immunization
✔ Median lead molecules: Over 40

✔ Large library capacity and definite sequences
✔ Diversified antigens, mouse, immunization method, and screening method
✔ Single domain antibody obtained directly
✔ Median lead molecules: Over 30


2.2. Featured Platform II: Antibody engineering platform

✔ 3D deep humanization design
✔ Distinctive database with reliable design

✔ Rich project experience and high success rate

✔ Eukaryotic expression system with natural modification

✔ Fast and qualified delivery within 4 to 6 weeks


✔ Ultimate improvement of affinity activity
✔ Comprehensive verification of eukaryotic expression
✔ No limit on target types
✔ Rich project R&D experience
✔ Fast and qualified delivery within 6 weeks


2.3. Featured Platform III: Platform for efficacy evaluation in animal models

✔ Variety of mouse strains and disease models
✔ Standardized animal room and management system
✔ High-quality and customized one-stop service
✔ Rich project R&D experience
✔ Fast and qualified delivery within 56 days


2.4. Featured Platform IV: Platform for production cell line development

✔ High yield: Expression level of bispecific monoclonal antibody cell line in flask is up to 9.0 g/L
✔ Stable production: Over 60 PDL assessments are performed to support commercialized production.
✔ Premium quality: 11 assessment indicators are used to ensure expression production quality.
✔ Good compliance: cGMP standards are adopted and 4 sets of commercially authorized host cells are available.
✔ Ultra fast: It takes only 2.5 months to obtain monoclonal cell lines.


2.5. Featured Platform V: Platform for antibody fermentation process development

✔ Antibody yield up to 12 g/L
✔ Compliance with antibody quality standards
✔ Four sets of authorized host cells
3. Extensive project experience

As of May 2022, Sanyou Bio has developed more than 100 pre-PCC, PCC and pre-clinical projects, and has accumulated rich project experience in antibody drug development targeting different disease fields, molecular types and MOA types, which guarantees the smooth progress of customer projects.


Fig. 1 Statistics of projects in different disease fields


Fig. 2 Statistics of projects in different molecular types


Fig. 3 Statistics of projects in different MOA types